Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Please provide your email address to receive an email when new articles are posted on . Graeme Jones, PhD, and colleagues randomly assigned 223 patients with symptomatic knee OA and subchondral bone ...

Imagine going to the doctor’s office once a year for treatment of a chronic medical condition. No daily pills. No weekly therapies. Just 30 minutes or so in a clinic. It could happen. A new ...

SAN ANTONIO (AP) - One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from ...

Zoledronic acid, while a bisphosphonate itself, is much more potent, and needs only to be given in a once-yearly infusion. In this randomised controlled trial, Professor David M Reid, University of ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Intravenous administration of bisphosphonates such as zoledronic acid can reduce the risk of fractures in postmenopausal women with osteoporosis, but some studies have shown such treatment to be ...

The oral bisphosphonate risedronate is currently used to treat patients with Paget's disease. Therapy, however, requires daily oral dosing for 2–6 months in a complex regimen that could result in ...

Impact of palliative care on end-of-life management of cancer patients dying in the hospital. Assessment of the current implementation and barriers to uptake of the guidelines for the psychosocial ...

CHICAGO It is the first large study to affirm wider anti-cancer hopes for Zometa and other bone-building drugs called bisphosphonates. Zometa, made by Novartis AG, is used now for cancers that have ...

The advent of bisphosphonates advanced therapy for Paget's disease, but more effective and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as a ...